loading
Cumberland Pharmaceuticals Inc stock is traded at $1.37, with a volume of 2.13M. It is up +23.42% in the last 24 hours and up +12.30% over the past month. Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
See More
Previous Close:
$1.11
Open:
$1.12
24h Volume:
2.13M
Relative Volume:
32.96
Market Cap:
$15.65M
Revenue:
$37.79M
Net Income/Loss:
$-10.38M
P/E Ratio:
-10.54
EPS:
-0.13
Net Cash Flow:
$-1.00M
1W Performance:
+25.69%
1M Performance:
+12.30%
6M Performance:
-11.61%
1Y Performance:
-17.96%
1-Day Range:
Value
$1.07
$1.59
1-Week Range:
Value
$1.04
$1.59
52-Week Range:
Value
$1.04
$2.3587

Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile

Name
Name
Cumberland Pharmaceuticals Inc
Name
Phone
615-255-0068
Name
Address
2525 WEST END AVENUE, NASHVILLE,, TN
Name
Employee
91
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
CPIX's Discussions on Twitter

Compare CPIX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
CPIX
Cumberland Pharmaceuticals Inc
1.37 15.65M 37.79M -10.38M -1.00M -0.13
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
176.74 80.59B 9.15B 2.43B 2.31B 4.92
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.72 44.17B 14.26B 1.55B 0 0.3327
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.57 42.61B 30.27B 1.93B 3.45B 0.444
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.57 18.77B 16.77B -959.00M 1.37B -2.00
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
13.22 15.73B 15.05B -883.30M 1.89B 1.53

Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-12-12 Reiterated UBS Neutral
Feb-01-11 Reiterated UBS Neutral
Dec-16-10 Downgrade UBS Buy → Neutral
Aug-17-10 Downgrade Jefferies Buy → Hold
Aug-17-10 Reiterated Morgan Joseph Buy
Aug-17-10 Reiterated UBS Buy
May-14-10 Reiterated Morgan Joseph Buy
View All

Cumberland Pharmaceuticals Inc Stock (CPIX) Latest News

pulisher
Nov 27, 2024

Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by Analysts at StockNews.com - Defense World

Nov 27, 2024
pulisher
Nov 26, 2024

Cumberland Pharma stock hits 52-week low at $1.04 By Investing.com - Investing.com Nigeria

Nov 26, 2024
pulisher
Nov 25, 2024

Cumberland Pharma stock hits 52-week low at $1.04 - Investing.com

Nov 25, 2024
pulisher
Nov 20, 2024

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Corneal Ulcer Treatment Market 2034: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail

Nov 20, 2024
pulisher
Nov 20, 2024

StockNews.com Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX) - Defense World

Nov 20, 2024
pulisher
Nov 19, 2024

Ibuprofen Injection Shows Better Real-World Outcomes in Comparative Study - Pharmacy Practice News

Nov 19, 2024
pulisher
Nov 15, 2024

Cumberland Pharma stock hits 52-week low at $1.07 - Investing.com

Nov 15, 2024
pulisher
Nov 15, 2024

Cumberland Pharma stock hits 52-week low at $1.07 By Investing.com - Investing.com UK

Nov 15, 2024
pulisher
Nov 12, 2024

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Cumberland Partners Ltd - MarketBeat

Nov 12, 2024
pulisher
Nov 10, 2024

Ibuprofen injection exhibits kidney safety with cost benefits over ketorolac: Study - Medical Dialogues

Nov 10, 2024
pulisher
Nov 10, 2024

Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023) - Yahoo Finance UK

Nov 10, 2024
pulisher
Nov 09, 2024

Cumberland Pharmaceuticals Inc. (CPIX) Quarterly 10-Q Report - Quartzy

Nov 09, 2024
pulisher
Nov 08, 2024

Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ... By GuruFocus - Investing.com Canada

Nov 08, 2024
pulisher
Nov 08, 2024

Cumberland: Q3 Earnings Snapshot - mySA

Nov 08, 2024
pulisher
Nov 08, 2024

Cumberland Pharmaceuticals Reports Q3 2024 Earnings and Developments - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Cumberland Pharmaceuticals Inc (CPIX) Reports Q3 2024 Revenue of $9.1 Million and EPS Loss of $0.11 - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire UK

Nov 06, 2024
pulisher
Nov 06, 2024

Cumberland's Ifetroban Secures Dual FDA Designations for Rare DMD Treatment | CPIX Stock | CPIX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

Cumberland Pharmaceuticals director James Jones buys $1,827 in stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Cumberland Pharmaceuticals CEO A.J. Kazimi buys $1,827 in stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Cumberland Pharmaceuticals director Caroline Young acquires $913 in stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Cumberland Pharmaceuticals director James Jones buys $1,827 in stock By Investing.com - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Cumberland's Caldolor Shows 78% Better Safety Than Ketorolac in Landmark 150K Patient Study | CPIX Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS - Citizentribune

Nov 04, 2024
pulisher
Nov 04, 2024

Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight - PR Newswire UK

Nov 04, 2024
pulisher
Nov 04, 2024

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt? - Simply Wall St

Nov 04, 2024
pulisher
Oct 31, 2024

Cumberland Pharma stock hits 52-week low at $1.18 By Investing.com - Investing.com Australia

Oct 31, 2024
pulisher
Oct 30, 2024

Cumberland Pharma stock hits 52-week low at $1.18 - Investing.com India

Oct 30, 2024
pulisher
Oct 30, 2024

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size, Share Analysis And Growth Statistics By 2033 - WhaTech

Oct 30, 2024
pulisher
Oct 29, 2024

Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - India Shorts

Oct 29, 2024
pulisher
Oct 29, 2024

Bacterial Pneumonia Market Expected to See Prominent Growth - openPR

Oct 29, 2024
pulisher
Oct 29, 2024

Complicated Skin And Skin Structure Infections Drugs Market Insights Discussed Regarding Share, Trends, Siz... - WhaTech

Oct 29, 2024
pulisher
Oct 25, 2024

Idiopathic Pulmonary Fibrosis Ipf Market Size and Growth - openPR

Oct 25, 2024
pulisher
Oct 23, 2024

Scleroderma Market to Witness Significant Growth by 2031 | Pfizer, Inc., Sanofi, GlaxoSmithKline plc - openPR

Oct 23, 2024
pulisher
Oct 23, 2024

Cumberland Pharma stock hits 52-week low at $1.19 By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 22, 2024

Cumberland Pharma stock hits 52-week low at $1.19 - Investing.com

Oct 22, 2024
pulisher
Oct 21, 2024

Vasopressin Market Huge Growth in Future Scope 2024-2031 | Par - openPR

Oct 21, 2024
pulisher
Oct 20, 2024

Shareholders have faith in loss-making Phathom Pharmaceuticals (NASDAQ:PHAT) as stock climbs 6.6% in past week, taking one-year gain to 74% - Simply Wall St

Oct 20, 2024
pulisher
Oct 17, 2024

Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail

Oct 17, 2024
pulisher
Oct 17, 2024

Cumberland Pharmaceuticals (NASDAQ:CPIX) Research Coverage Started at StockNews.com - Defense World

Oct 17, 2024
pulisher
Oct 15, 2024

Scleroderma Diagnostics and Therapeutics Market – 37% of Growth to Originate from APAC -Actelion Pharmaceuticals, Inc., – உங்கள் குரல் - உங்கள் குரல்

Oct 15, 2024
pulisher
Oct 15, 2024

Cooling Paste Market Growing Rapidly by-Kobayashi Pharmaceutical, Hisamitsu Pharmaceutical, Pigeon, New Tac Kasei, Sato – IndiaPolitics.com - IndiaPolitics.com

Oct 15, 2024
pulisher
Oct 14, 2024

Ibuprofen Injection Industry to Witness Massive Growth (2024-2034) |Cumberland Pharmaceuticals, CSL Limited, Akorn, Inc. – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 14, 2024

Cooling Paste Industry to Witness an Outstanding Growth by 2030 |Kobayashi Pharmaceutical, Hisamitsu Pharmaceutical, Pig – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 14, 2024

Drugs for Xerostomia Market Future Developments – Concordia, AMICI, Aurobindo Pharma Ltd, Impax Labs - Cauverynews

Oct 14, 2024
pulisher
Oct 11, 2024

Burn Pain Market Expected to Experience Major Growth by 2034, - openPR

Oct 11, 2024

Cumberland Pharmaceuticals Inc Stock (CPIX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$90.27
price up icon 0.83%
$13.13
price up icon 0.00%
$86.59
price up icon 0.19%
$61.00
price up icon 0.41%
$126.59
price down icon 1.03%
$13.22
price up icon 1.07%
Cap:     |  Volume (24h):